Angiogenic and inflammatory markers in the intraocular fluid of eyes with diabetic macular edema and influence of therapy with bevacizumab

Retina

Volumn 30, Issue 9, 2010, Pages 1412-1419

  Funk, Marion ^a   Schmidinger, Gerald ^a   Maar, Noemi ^a   Bolz, Matthias ^a   Benesch, Thomas ^a   Zlabinger, Gerhard J ^b   Schmidt Erfurth, Ursula M ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

aqueous humor; diabetic macular edema; IL 6; IL 8; interleukins; intravitreal bevacizumab; MCP 1; vascular endothelial growth factor

Indexed keywords

BEVACIZUMAB; INTERLEUKIN 6; INTERLEUKIN 8; MONOCYTE CHEMOTACTIC PROTEIN 1; VASCULOTROPIN;

AGED; AQUEOUS HUMOR; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DIABETIC MACULAR EDEMA; DISEASE ACTIVITY; FOLLOW UP; HUMAN; MEASUREMENT; PROTEIN EXPRESSION; RETREATMENT; VISUAL ACUITY;

AGED; ANGIOGENESIS INHIBITORS; ANGIOGENIC PROTEINS; ANTIBODIES, MONOCLONAL; AQUEOUS HUMOR; BIOLOGICAL MARKERS; CHEMOKINE CCL2; DIABETIC RETINOPATHY; HUMANS; INFLAMMATION MEDIATORS; INTERLEUKIN-8; INTRAVITREAL INJECTIONS; MACULAR EDEMA; PROSPECTIVE STUDIES; RETREATMENT; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 78049283701     PISSN: 0275004X     EISSN: None     Source Type: Journal    
DOI: 10.1097/IAE.0b013e3181e095c0     Document Type: Article

References (43)

1. Porta M, Bandello F. Diabetic retinopathy. A clinical update. Diabetologia 2002;45:1617-1634.
2. Klein R, Klein B, Moss S, Cruickshanks K. The Wisconsin Epidemiologic Study of Diabetic Retinopathy XV. The longterm incidence. Ophthalmology 1995;102:7-16.
3. Sheetz M, King G. Molecular understanding of hyperglyce-mia's adverse effects for diabetic complications. JAMA 2002; 288:2579-2588. (Pubitemid 35386893)
4. Pendergast S. Vitrectomy for diabetic macular edema associated with a taut premacular posterior hyaloid. Curr Opin Ophthalmol 1998;9:71-75. (Pubitemid 28379972)
5. Henricsson M, Sellman A, Tyrberg M, et al. Progression to proliferative retinopathy and macular oedema requiring treatment. Assessment of the alternative classification of the Wisconsin Study. Acta Ophthalmol Scand 1999;77:218-223. (Pubitemid 29164066)
6. Qaum T, Xu Q, Joussen AM, et al. VEGF-initiated blood-retinal barrier breakdown in early diabetes. Invest Ophthalmol Vis Sci 2001;42:2408-2413. (Pubitemid 32848873)
7. Aiello LP, Northrup JM, Keyt BA, et al. Hypoxic regulation of vascular endothelial growth factor in retinal cells. Arch Ophthalmol 1995;113:1538-1544.
8. Vinores S, Youssri A, Luna J, et al. Upregulation of vascular endo-thelial growth factor in ischemic and non-ischemic human and experimental retinal disease. Histol Histopathol 1997;12:99-109. (Pubitemid 27106924)
9. Lutty G, McLeod D, Merges C, et al. Localization of vascular endothelial growth factor in human retina and choroid. Arch Ophthalmol 1996;114:971-977. (Pubitemid 26271463)
10. Mathews M, Merges C, McLeod D, Lutty G. Vascular endothelial growth factor and vascular permeability changes in human diabetic retinopathy. Invest Ophthalmol Vis Sci 1997;38:2729-2741. (Pubitemid 28009394)
11. Clauss M, Weich H, Breier M, et al. The vascular endothelial growth factor receptor Flt-1 mediates biological activities. Implications for a functional role of placenta growth factor in monocyte activation and chemotaxis. J Biol Chem 1996;271: 17629-17634. (Pubitemid 26250731)
12. Melder R, Koenig G, Witwer B, et al. During angiogenesis, vascular endothelial growth factor and basic fibroblast growth factor regulate natural killer cell adhesion to tumor endothe-lium. Nature Med 1996;2:992-997. (Pubitemid 26306837)
13. Witmer A, Vrensen G, van Noorden C, Schlingemann R. Vascular endothelial growth factors and angiogenesis in eye disease. Prog Retin Eye Res 2003;22:1-29. (Pubitemid 36207453)
14. Grant M, Afzal A, Spoerri P, et al. The role of growth factors in the pathogenesis of diabetic retinopathy. Expert Opin Investig Drugs 2004;13:1275-1293. (Pubitemid 39359658)
15. Early Treatment Diabetic Retinopathy Study Research group. Photocoagulation for diabetic macular edema. Early treatment diabetic retinopathy study report number 1. Arch Ophthalmol 1985;103:1796-1806.
16. Early Treatment Diabetic Retinopathy Study Research group. Treatment techniques and clinical guidelines for photocoagulation of diabetic macular edema. Early treatment diabetic retinopathy study report number 2. Ophthalmology 1987; 94: 761-774.
17. Haritoglou C, Kook D, Neubauer A, et al. Intravitreal bevacizumab (Avastin) therapy for persistent diffuse diabetic macular edema. Retina 2006;26:999-1005. (Pubitemid 44973218)
18. Diabetic Retinopathy Clinical Research Network, Scott I, Edwards A, et al. A phase II randomized clinical trial of intravitreal bevacizumab for diabetic macular edema. Ophthalmology 2007;114:1860-1867.
19. Arevalo J, Fromow-Guerra J, Quiroz-Mercado H, et al. Primary intravitreal bevacizumab (Avastin) for diabetic macular edema: results from the Pan-American collaborative retina study group at 6-month follow-up. Ophthalmology 2007;114:743-750. (Pubitemid 46483714)
20. Scott I, Edwards A, Bexk R, et al. A phase II randomized clinical trial of intravitreal bevacizumab for diabetic macular edema. Ophthalmology 2007;114:1860-1867.
21. Early Treatment Diabetic Retinopathy Study Research Group. Fundus photographic risk factors for progression of diabetic retinopathy. ETDRS report number 12. Ophthalmology 1991;98: 823-833.
22. Krohne TU, Eter N, Holz FG, Meyer CH. Intraocular pharmacokinetics of bevacizumab after a single intravitreal injection in humans. Am J Ophthalmol 2008;146: 508-512.
23. Sawada O, Kawamura H, Kakinoki M, et al. Vascular endothelial growth factor in aqueous humor before and after intravitreal injection of bevacizumab in eyes with diabetic retinopathy. Arch Ophthalmol 2007;125:1363-1366. (Pubitemid 47606601)
24. Funk M, Kriechbaum K, Prager F, et al. Intraocular concentrations of growth factors and cytokines in retinal vein occlusion and the effect of therapy with bevacizumab. Invest Ophthalmol Vis Sci 2009;50:1025-1032.
25. Funatsu H, Noma H, Mimura T, et al. Association of vitreous inflammatory factors with diabetic macular edema. Ophthalmology 2009;116:73-79.
26. Maier R, Weger M, Haller-Schober EM, et al. Multiplex bead analysis of vitreous and serum concentrations of inflammatory and proangiogenic factors in diabetic patients. Mol Vis 2008; 14:637-643. (Pubitemid 351486723)
27. Funatsu H, Yamashita H, Noma H, et al. Aqueous humor levels of cytokines are related to vitreous levels and progression of diabetic retinopathy in diabetic patients. Graefes Arch Clin Exp Ophthalmol 2005;243:3-8.
28. Noma H, Funatsu H, Yamasaki M, et al. Aqueous humour levels of cytokines are correlated to vitreous levels and severity of macular oedema in branch retinal vein occlusion. Eye 2008;22: 42-48.
29. Petrovic M, Korosec P, Kosnik M, Hawlina M. Vitreous levels of interleukin-8 in patients with proliferative diabetic retinopathy. Am J Ophthalmol 2007;143:175-176. (Pubitemid 44917800)
30. Hernández C, Segura R, Fonollosa A, et al. Interleukin-8, monocyte chemoattractant protein-1 and IL-10 in the vitreous fluid of patients with proliferative diabetic retinopathy. Diabet Med 2005;22:719-722. (Pubitemid 40805892)
31. Shakoory B, Fitzgerald SM, Lee SA, Krishnaswamy GJ. The role of human mast cell-derived cytokines in eosinophil biology. J Interferon Cytokine Res 2004;24:271-281. (Pubitemid 38648308)
32. Hong K, Ryu J, Han K. Monocyte chemoattractant protein-1-induced angiogenesis is mediated by vascular endothelial growth factor-A. Blood 2005;105:1405-1407. (Pubitemid 40223654)
33. Caldwell RB, Bartoli M, Behzadian MA, et al. Vascular endothelial growth factor and diabetic retinopathy: pathophys-iological mechanisms and treatment perspectives. Diabetes Metab Res Rev 2003;19:442-455. (Pubitemid 37536961)
34. Zhang J, Gerhardinger C, Lorenzi M. Early complement activation and decreased levels of glycosylphosphatidylinositol-anchored complement inhibitors in human and experimental diabetic retinopathy. Diabetes 2002;51:3499-3504. (Pubitemid 35403456)
35. Joussen A, Poulaki V, Le M, et al. A central role for inflammation in the pathogenesis of diabetic retinopathy. FASEB J 2004;18:1450-1452. (Pubitemid 39561611)
36. Tesch GH. Role of macrophages in complications of type 2 diabetes. Clin Exp Pharmacol Physiol 2007;34:1016-1019. (Pubitemid 47274561)
37. Graves DT, Kayal RA. Diabetic complications and dysregu-lated innate immunity. Front Biosci 2008;1:1227-1239.
38. Jonas J, Neumaier M. Vascular endothelial growth factor and basic fibroblast growth factor in exudative age-related macular degeneration and diffuse diabetic macular edema. Ophthalmic Res 2007;39:139-142. (Pubitemid 46975978)
39. Patel J, Tombran-Tink J, Hykin P, et al. Vitreous and aqueous concentrations of proangiogenic, antiangiogenic factors and other cytokines in diabetic retinopathy patients with macular edema: implications for structural differences in macular profiles. Exp Eye Res 2006;82:798-806. (Pubitemid 43170880)
40. Funatsu H, Yamashita H, Noma H, et al. Increased levels of vascular endothelial growth factor and interleukin-6 in the aqueous humor of diabetics with macular edema. Am J Ophthalmol 2002;133:70-77. (Pubitemid 34076505)
41. Funatsu H, Yamashita H, Ikeda T, et al. Relation of diabetic macular edema to cytokines and posterior vitreous detachment. Am J Ophthalmol 2003;135:321-327. (Pubitemid 36279518)
42. Funatsu H, Yamashita H, Sakata K, et al. Vitreous levels of vascular endothelial growth factor and intercellular adhesion molecule 1 are related to diabetic macular edema. Ophthalmology 2005;112:806-816. (Pubitemid 40631499)
43. Funk M, Karl D, Georgopoulos M, et al. Neovascular age-related macular degeneration: intraocular cytokines and growth factors and the influence of therapy with ranibizumab. Ophthalmology 2009;116:2393-2399